comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists SGLT2 vs GLP-1: Individualizing Diabetes, Cardiovascular, Renal Free Comparison Chart: GLP-1 and
Description
Acta Materia Med
Researchers have found that semaglutide and tirzepatide help reduce cardiovascular disease and prevent sleep apnea
Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea
Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials
Narula said the good news is that GLP-1 medications have been successfully shown to help people lose some weight overall
FDA warning: Risk of thyroid cancer This drug has a boxed warning
